Otsuka and Acucela strike two-way ophthalmic pact
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceuticaland the US venture Acucela have agreed to co-develop each other's ophthalmic products, including a novel therapy for dry age-related macular degeneration.